Harm Reduction and Palliative Care: Is There A Role for Supervised Drug Consumption Services?

Mathers B.M. , Degenhardt L. , Phillips B. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 2008; 372(9651): 1733–1745.

Werb D. , DeBeck K. , Kerr T Modelling crack cocaine use trends over 10 years in a Canadian setting. Drug Alcohol Rev 2010; 29(3): 271–277.

Maxwell J.C. , Rutkowski B.A. The prevalence of methamphetamine and amphetamine abuse in North America: a review of the indicators, 1992–2007. Drug Alcohol Rev 2008; 27(3): 229–235.

DeBeck K. , Kerr T. , Li K. Smoking of crack cocaine as a risk factor for HIV infection among people who use injection drugs. CMAJ 2009; 181(9): 585–589.

Plankey M.W. , Ostrow D.G. , Stall R. The relationship between methamphetamine and popper use and risk of HIV seroconversion in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 2007; 45(1): 85–92.

Tyndall M.W. , Currie S. , Spittal P. Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic. AIDS 2003; 17(6): 887–893.

Hagan H. Hepatitis C virus transmission dynamics in injection drug users. Subst Use Misuse 1998; 33(5): 1197–1212.

Roy E. , Haley N. , Leclerc P. Risk factors for hepatitis C virus infection among street youths. CMAJ, 165(5): 557–560.

Alter M.J. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44(1 Suppl): S86–S89.

Puoti M. , Bruno R. , Soriano V. Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS 2004; 18(17): 2285–2293.

Lucas G.M. , Griswold M. , Gebo K.A. Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy. Am J Epidemiol 2006; 163(5): 412–420.

Wolfe D. , Carrieri M.P. , Shepard D. Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward. Lancet 2010; 376(9738): 355–366.

Degenhardt L. , Singleton J. , Calabria B. Mortality among cocaine users: a systematic review of cohort studies. Drug Alcohol Depend 2011; 113(2-3): 88–95.

Spittal P. , Hogg R.S. , Li K. Drastic elevations in mortality among female injection drug users in a Canadian setting. AIDS Care 2006; 18(2): 101–108.

Bhaskaran K. , Hamouda O. , Sannes M. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 2008; 300(1): 51–59.

McNeil R. , Guirguis-Younger M. Illicit drug use as a challenge to the delivery of end-of-life care services to homeless persons: perceptions of health and social services professionals. Palliat Med 2012; 26(4): 350–359.

Cagle J. Weathering the storm: palliative care and elderly homeless persons. J Hous Elderly 2009; 23(1-2): 29–46.

McNeil R. , Guirguis-Younger M. , Dilley L.B. Harm reduction services as a point-of-entry to and source of end-of-life care and support for homeless and marginally housed persons who use alcohol and/or illicit drugs: a qualitative analysis. BMC Pub Health 2012; 12: 312.

Podymow T. , Turnbull J. , Coyle D. Shelter-based palliative care for the homeless terminally ill. Palliat Med 2006; 20(2): 81–86.

Kerr T. , Palepu A. Safe injection facilities in Canada: is it time? CMAJ 2001; 165(4): 436–437.

Wood E. , Kerr T. , Lloyd-Smith E. Methodology for evaluating Insite: Canada's first medically supervised safer injection facility for injection drug users. Harm Reduct J 2004; 1(1): 9.

Wood E. , Tyndall M.W. , Li K. Do supervised injecting facilities attract higher-risk injection drug users? Am J Prev Med 2005; 29(2): 126–130.

Kerr T. , Tyndall M. , Li K. Safer injection facility use and syringe sharing in injection drug users. Lancet 2005; 366(9482): 316–318.

Kerr T. , Tyndall M.W. , Lai C. Drug-related overdoses within a medically supervised safer injection facility. Int J Drug Policy 2006; 17(5): 436–441.

Tyndall M.W. , Kerr T. , Zhang R. Attendance, drug use patterns, and referrals made from North America's first supervised injection facility. Drug Alcohol Depend 2006; 83(3): 193–198.

Krüsi A. , Small W. , Wood E. An integrated supervised injecting program within a care facility for HIV-positive individuals: a qualitative evaluation. AIDS Care 2009; 21(5): 638–644.

Rachlis B.S. , Kerr T. , Montaner J. Harm reduction in hospitals: is it time? Harm Reduct J 2009; 6(19): 1–4.

Gilbert M. , Buxton J. , Tupper K. Decreasing HIV infections among people who use drugs by injection in British Columbia: potential explanations and recommendations for further action. Report from the Office of the Provincial Health Officer. Victoria (BC): Ministry of Health; 2011 Mar.

National Specialty Society for Community Medicine. Supervised drug consumption sites and Insite program. Ottawa: author; 2009.

Canada (Attorney General) v. PHS Community Services Society, 2011 SCC 44, [2011] 3 S.C.R. 134.

Kerr T. , Kimber J. , DeBeck K. The role of safer injection facilities in the response to HIV/AIDS among injection drug users. Curr HIV/AIDS Rep 2007; 4(4): 158–164.